Drug Humira turns Rheumatic for Abbott Biotechnology
The Indian Patent Office set aside Abbott Biotechnology's Humira patent after Glenmark's pre-grant opposition, citing lack of inventive step and insufficient disclosure. This legal dispute underscores ongoing challenges…